In today’s rapidly evolving global economy, businesses are under constant pressure to innovate, scale, and stay competitive. Traditional cost-cutting measures are no longer sufficient. Instead, strategic outsourcing has emerged as a powerful lever for growth—especially in the life sciences sector.
This session will delve into:
- The evolution of outsourcing from a cost-saving tactic to a strategic growth enabler
- Key trends driving the expansion of the biologics CDMO market
- How companies are building meaningful partnerships to streamline operations and foster innovation
Whether you’re a biotech startup or an established pharmaceutical company, this webinar will provide valuable insights into leveraging outsourcing as a strategic advantage in a competitive landscape.
Join us for an insightful webinar exploring the rise of strategic outsourcing and its transformative impact on the biologics industry. With the Biologics CDMO market projected to grow from $10.59 billion in 2024 to $16.36 billion by 2030, organizations—particularly virtual and lean enterprises—are increasingly turning to Contract Development and Manufacturing Organizations (CDMOs) and Contract Research Organizations (CROs) to access specialized expertise, accelerate timelines, and reduce infrastructure costs.
Speaker Bio
Samantha , PhD
With a deep expertise in biologics and a passion for translating innovation into scalable solutions, Samantha Hullah has over 15 years of experience in the CDMO industry. She has led downstream recombinant protein purification programs as Technical Lead and managed viral gene therapy process development and manufacturing as Head of Site. In her current role she provides technical and CMC advice to Syngene’s potential biologics customers. She also serves as the technical liaison between front line sales and operations teams. Based in Cambridge, Massachusetts today, she hails from the North East of England and supports a global commercial team.
